share_log

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.63%)

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.63%)

诺瓦瓦克斯医药 | SC 13G/A：超过5%持股股东披露文件(修正)-The Vanguard Group(9.63%)
美股SEC公告 ·  2024/11/05 02:24

Moomoo AI 已提取核心信息

The Vanguard Group has filed an amendment to its Schedule 13G, indicating a change in its holdings of Novavax Inc common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 15,430,034 shares of Novavax, representing 9.63% of the company's class of common stock. The filing, made under Rule 13d-1(b) of the Securities Exchange Act of 1934, shows that The Vanguard Group has shared voting power over 224,741 shares and sole dispositive power over 15,072,218 shares, with an additional shared dispositive power over 357,816 shares. This amendment reflects The Vanguard Group's position as a significant investor in Novavax, with the reported shares being held on behalf of its clients, including registered investment companies and other managed accounts.
The Vanguard Group has filed an amendment to its Schedule 13G, indicating a change in its holdings of Novavax Inc common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 15,430,034 shares of Novavax, representing 9.63% of the company's class of common stock. The filing, made under Rule 13d-1(b) of the Securities Exchange Act of 1934, shows that The Vanguard Group has shared voting power over 224,741 shares and sole dispositive power over 15,072,218 shares, with an additional shared dispositive power over 357,816 shares. This amendment reflects The Vanguard Group's position as a significant investor in Novavax, with the reported shares being held on behalf of its clients, including registered investment companies and other managed accounts.
先锋集团已经提交了一份修订版的13G申报，表明其持有诺瓦瓦克斯医药普通股的情况发生了变化。截至2024年9月30日，先锋集团报告持有15,430,034股诺瓦瓦克斯医药股票，占公司普通股类别的9.63%。根据1934年证券交易法案第13d-1(b)条款的规定提交的申报显示，先锋集团对224,741股股份享有投票权，并拥有对15,072,218股的唯一支配权，另外还有对357,816股股份的共同支配权。这份修订案反映了先锋集团作为诺瓦瓦克斯医药的重要投资者，报告的股份是代表其客户持有的，包括注册的投资公司和其他托管账户。
先锋集团已经提交了一份修订版的13G申报，表明其持有诺瓦瓦克斯医药普通股的情况发生了变化。截至2024年9月30日，先锋集团报告持有15,430,034股诺瓦瓦克斯医药股票，占公司普通股类别的9.63%。根据1934年证券交易法案第13d-1(b)条款的规定提交的申报显示，先锋集团对224,741股股份享有投票权，并拥有对15,072,218股的唯一支配权，另外还有对357,816股股份的共同支配权。这份修订案反映了先锋集团作为诺瓦瓦克斯医药的重要投资者，报告的股份是代表其客户持有的，包括注册的投资公司和其他托管账户。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间